Valuation: Gilead Sciences, Inc.

Market Cap 181B 155B 145B 133B 249B 17,337B 253B 1,714B 668B 8,703B 680B 665B 28,797B P/E 2026 *
-44.6x
P/E 2027 * 18.2x
Enterprise Value 198B 169B 159B 145B 272B 18,940B 276B 1,873B 730B 9,507B 743B 727B 31,459B EV / Sales 2026 *
6.45x
EV / Sales 2027 * 5.82x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.32%
1 day+1.97%
1 week+5.84%
Current month+12.18%
1 month+9.48%
3 months+11.38%
6 months-4.37%
Current year+16.88%
1 week 28.07
Extreme 28.07
30.01
1 month 25.84
Extreme 25.84
30.01
Current year 23.97
Extreme 23.97
31.8
1 year 22.49
Extreme 22.49
31.8
3 years 20.08
Extreme 20.08
31.8
5 years 20.08
Extreme 20.08
31.8
10 years 20.08
Extreme 20.08
31.8
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+5.84% - - 178B
+0.88%+3.84%+77.96%+129.75% 1,109B
+1.07%+3.11%+51.11%+56.67% 644B
+1.20%+5.64%+26.68%+76.48% 463B
+1.02%+3.67%+43.14%+47.27% 371B
+0.85%+2.97%+24.48%+42.54% 301B
+1.26%+4.54%+2.20%+14.84% 256B
+1.88%+5.14%+48.20%+67.80% 234B
+1.59%+0.87%-12.95%-51.91% 205B
+1.87%+5.78%+23.07%+92.57% 178B
Average +1.04%+3.00%+31.54%+52.89% 417.9B
Weighted average by Cap. +0.58%+3.26%+44.79%+72.24%

Financials

2026 *2027 *
Net sales 30.69B 26.28B 24.58B 22.5B 42.24B 2,937B 42.81B 290B 113B 1,474B 115B 113B 4,878B 32.7B 28B 26.18B 23.97B 45B 3,129B 45.61B 309B 121B 1,571B 123B 120B 5,197B
Net income -4.27B -3.66B -3.42B -3.13B -5.88B -409B -5.96B -40.45B -15.77B -205B -16.05B -15.7B -679B 10.28B 8.8B 8.23B 7.53B 14.14B 983B 14.33B 97.22B 37.89B 494B 38.58B 37.73B 1,633B
Net Debt 16.75B 14.34B 13.41B 12.28B 23.05B 1,602B 23.36B 158B 61.76B 804B 62.87B 61.5B 2,661B 9.12B 7.81B 7.31B 6.69B 12.56B 873B 12.73B 86.34B 33.65B 438B 34.26B 33.51B 1,450B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
21/08/26 CA$29.56 +1.97% 2,030
20/08/26 CA$28.99 -3.30% 2,248
19/08/26 CA$29.98 +3.70% 1,313
18/08/26 CA$28.91 +2.99% 693
17/08/26 CA$28.07 +0.43% 386
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
146.12USD
Average target price
157.41USD
Spread / Average Target
+7.72%

Quarterly revenue - Rate of surprise